About

Bortezomib is an antineoplastic agent classified as a proteasome inhibitor. It works by reversibly inhibiting the 26S proteasome, a large protein complex responsible for degrading ubiquitinated proteins. This inhibition leads to the accumulation of misfolded and ubiquitinated proteins within cancer cells, disrupting various cellular processes such as cell cycle progression, angiogenesis, and apoptosis. The accumulation of these proteins triggers endoplasmic reticulum stress and activates pro-apoptotic pathways, ultimately leading to the programmed cell death of malignant cells. Its selective action against cancer cells makes it a crucial component in the treatment of specific hematological malignancies.

Administered intravenously or subcutaneously, bortezomib has demonstrated significant efficacy in improving patient outcomes by targeting key survival pathways in cancer cells. Its unique mechanism of action distinguishes it from conventional chemotherapeutic agents, offering a targeted approach to cancer therapy. Regular monitoring of patient response and potential side effects is essential throughout the treatment course to optimize therapeutic benefits and manage adverse reactions effectively.

Uses

Treatment of multiple myeloma.
Management of mantle cell lymphoma.
Used in combination with other agents for specific indications.
For patients who have received prior therapy or are newly diagnosed.

Directions For Use

Administered by a healthcare professional via intravenous or subcutaneous injection. Dosage and schedule are determined by the physician based on the patient's condition.

Benefits

Effective in treating specific blood cancers.
Can induce remission in refractory cases.
Improves overall survival in eligible patients.
Offers a targeted mechanism of action.
Can be used in combination therapies.
May reduce tumor burden and disease progression.

Side Effects

Peripheral neuropathy
Thrombocytopenia
Neutropenia
Anemia
Fatigue
Nausea and vomiting
Diarrhea or constipation
Fever
Rash
Headache
Muscle weakness
Hypotension

Safety Measures

Alcohol - Avoid or limit alcohol consumption as it may exacerbate certain side effects like liver toxicity or gastrointestinal issues.
Pregnancy - Bortezomib is contraindicated in pregnancy due to potential fetal harm. Effective contraception is required during treatment and for a period after.
Breastfeeding - Breastfeeding is not recommended during bortezomib treatment and for a period after, as the drug may pass into breast milk and harm the infant.
Liver - Use with caution in patients with hepatic impairment; dose adjustments may be necessary. Monitor liver function closely.
Kidney - Generally, no dose adjustment is required for renal impairment, but caution is advised. Monitor kidney function regularly.
Lung - Use with caution in patients with pre-existing pulmonary conditions; monitor for new or worsening pulmonary symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.

Shipping & Location